Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!

doi:10.1164/rccm.202112-2782ED

Editorial

. 2022 Mar 1;205(5):487-489.

doi: 10.1164/rccm.202112-2782ED.

Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!

Bonnie W Ramsey^{1

2}, Scott C Bell^{3

4

5}

Affiliations

¹ Department of Pediatrics University of Washington School of Medicine Seattle, Washington.
² Seattle Children's Research Institute Seattle, Washington.
³ Adult Cystic Fibrosis Centre The Prince Charles Hospital Brisbane, Australia.
⁴ Children's Health Research Centre The University of Queensland Brisbane, Australia.
⁵ Translational Research Institute Brisbane, Australia.

PMID: 35073504
PMCID: PMC8906488
DOI: 10.1164/rccm.202112-2782ED

Editorial

Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!

Bonnie W Ramsey et al. Am J Respir Crit Care Med. 2022.

. 2022 Mar 1;205(5):487-489.

doi: 10.1164/rccm.202112-2782ED.

Authors

Bonnie W Ramsey^{1

2}, Scott C Bell^{3

4

5}

Affiliations

¹ Department of Pediatrics University of Washington School of Medicine Seattle, Washington.
² Seattle Children's Research Institute Seattle, Washington.
³ Adult Cystic Fibrosis Centre The Prince Charles Hospital Brisbane, Australia.
⁴ Children's Health Research Centre The University of Queensland Brisbane, Australia.
⁵ Translational Research Institute Brisbane, Australia.

PMID: 35073504
PMCID: PMC8906488
DOI: 10.1164/rccm.202112-2782ED

No abstract available

PubMed Disclaimer

Comment on

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM; PROMISE Study group. Nichols DP, et al. Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC. Am J Respir Crit Care Med. 2022. PMID: 34784492 Free PMC article.
Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles.
Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, Sommerburg O, Dittrich AM, Tümmler B, Mall MA. Graeber SY, et al. Am J Respir Crit Care Med. 2022 Mar 1;205(5):540-549. doi: 10.1164/rccm.202110-2249OC. Am J Respir Crit Care Med. 2022. PMID: 34936849

Cited by

Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
Wang S, Niroula S, Hoffman A, Khorrami M, Khorrami M, Yuan F, Gasser GN, Choi S, Liu B, Li J, Metersky ML, Vincent M, Crum CP, Boucher RC, Karmouty-Quintana H, Huang HJ, Sheshadri A, Dickey BF, Parekh KR, Engelhardt JF, McKeon FD, Xian W. Wang S, et al. Am J Respir Crit Care Med. 2023 Nov 1;208(9):930-943. doi: 10.1164/rccm.202305-0818OC. Am J Respir Crit Care Med. 2023. PMID: 37695863 Free PMC article.
Changing racial and ethnic differences for lung transplantation in cystic fibrosis.
Hayes D Jr, Dani A, Guzman-Gomez A, Zafar F, Morales DLS, Ziady AG. Hayes D Jr, et al. Pediatr Transplant. 2023 Feb;27(1):e14404. doi: 10.1111/petr.14404. Epub 2022 Oct 7. Pediatr Transplant. 2023. PMID: 36206358 Free PMC article.

References

1. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. VX17-445-102 Study Group Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med . 2019;381:1809–1819. - PMC - PubMed
1. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. VX17-445-103 Trial Group Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet . 2019;394:1940–1948. - PMC - PubMed
1. Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, et al. PROMISE Study Group Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial Am J Respir Crit Care Med 2022205529–539 - PMC - PubMed
1. Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles Am J Respir Crit Care Med 2022205540–549 - PubMed
1. Nichols DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, et al. PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros . 2021;20:205–212. - PMC - PubMed

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- Genetic Alliance
- MedlinePlus Health Information

[1] Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. VX17-445-102 Study Group Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med . 2019;381:1809–1819. - PMC - PubMed

[2] Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. VX17-445-102 Study Group Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med . 2019;381:1809–1819. - PMC - PubMed

[3] Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. VX17-445-103 Trial Group Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet . 2019;394:1940–1948. - PMC - PubMed

[4] Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. VX17-445-103 Trial Group Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet . 2019;394:1940–1948. - PMC - PubMed

[5] Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, et al. PROMISE Study Group Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial Am J Respir Crit Care Med 2022205529–539 - PMC - PubMed

[6] Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, et al. PROMISE Study Group Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial Am J Respir Crit Care Med 2022205529–539 - PMC - PubMed

[7] Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles Am J Respir Crit Care Med 2022205540–549 - PubMed

[8] Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles Am J Respir Crit Care Med 2022205540–549 - PubMed

[9] Nichols DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, et al. PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros . 2021;20:205–212. - PMC - PubMed

[10] Nichols DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, et al. PROMISE: working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros . 2021;20:205–212. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!

Affiliations

Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical